A DNA prime-boost vaccination strategy produced one of the strongest peptide-specific CD8+ T cell responses ever recorded against the leukemia-associated antigen HA-1, with cytotoxic activity lasting over 12 months.
1.5% of CD8+ T cellsOne of the strongest primary peptide-specific T cell responses ever recorded to a DNA-MVA prime-boost regimen
What the researchers found
Seven of nine donors developed HA-1-specific CD8+ T cell responses up to 1.5% of total CD8+ repertoire after DNA-MVA prime-boost vaccination, with strong cytotoxic activity and responses detectable at 12 months.
Why it matters
Boosting anti-leukemia immune responses through vaccination could reduce relapse after stem cell transplant, which currently occurs in many patients despite otherwise successful transplantation.
The numbers in context
9 donors; 7 responders; up to 1.5% of CD8+ repertoire; >12 month responses; TRBV7-9 TCR conservation; strong cytotoxic activity against HA-1-expressing targets
How the study worked
Phase I clinical study. Nine HA-1-negative donors received 2-3 DNA priming vaccinations followed by modified vaccinia Ankara (MVA) boost. T cell responses measured by flow cytometry, cytotoxicity assays, and TCR repertoire analysis over 12 months.
Who was studied
Healthy HA-1-negative donors
What this study cannot tell us
Small study (9 donors). Vaccination was in healthy donors, not leukemia patients. Clinical anti-leukemia efficacy not tested. The approach requires HLA-matched donors who are HA-1 negative, limiting the eligible population.
How to read the evidence
Moderate evidence: Phase I clinical study with strong immunological results in 9 donors, but no clinical efficacy data against leukemia. Small sample size.
When this study was published
Published in 2021. mHAg-targeted vaccination strategies continue to be explored in clinical settings.
The bigger picture
Peptide-targeted vaccines for cancer immunotherapy are gaining traction. This study demonstrates that mHAg peptides can generate exceptionally strong immune responses, potentially complementing checkpoint inhibitors and CAR-T therapy for blood cancers.
Questions still open
- Would vaccinating leukemia patients post-transplant boost their graft-versus-leukemia response and reduce relapse?
- Can this vaccination approach be extended to other mHAg peptides beyond HA-1?
- Could the vaccinated donor T cells be transferred to patients as an adoptive cell therapy?
Common questions
What is HA-1 and why target it for leukemia?
How does this vaccine work?
Read the original research
DNA and modified vaccinia Ankara prime-boost vaccination generates strong CD8+ T cell responses against minor histocompatibility antigen HA-1.
British journal of haematology, 195(3), 433-446
Citation
Eldershaw, Suzy A; Pearce, Hayden; Inman, Charlotte F; Piper, Karen P; Abbotts, Ben; Stephens, Christine; Nicol, Samantha; Croft, Wayne; Powell, Richard; Begum, Jusnara; Taylor, Graham; Nunnick, Jane; Walsh, Donna; Sirovica, Mirjana; Saddique, Shamyla; Nagra, Sandeep; Ferguson, Paul; Moss, Paul; Malladi, Ram. (2021). DNA and modified vaccinia Ankara prime-boost vaccination generates strong CD8+ T cell responses against minor histocompatibility antigen HA-1.. British journal of haematology, 195(3), 433-446. https://doi.org/10.1111/bjh.17495